BIOXYNE LIMITED(BXN)

The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following the release by BXN of a clarification announcement to supplement the information required in relation to BXN's announcement "˜BXN Manufactures First Pharmaceuticals Cannabis Gummies' on 21 August 2024.

The company has signed a 2-year supply agreement with Montu group Pty Ltd for medicinal cannabis pastilles. The agreement has a fixed price for 24 months and a revenue estimate of $28 million. The company received a deposit of over $900,000 and may terminate the agreement if the customer fails to meet the terms.

On 12 September 2024, ASX required Bioxyne Limited to provide specified information for release to the market in relation to "˜a 2"year manufacture and supply agreement' as announced in BXN's announcement "˜BXN Manufactures First Pharmaceutical Cannabis Gummies' on 21 August 2024. BXN has failed to comply with that requirement. As a consequence, BXN's securities will be suspended from quotation immediately under Listing Rule 17.3.1, until such time as ASX is satisfied with BXN's compliance with the Listing Rules and that it is otherwise appropriate for BXN's securities to be reinstated to quotation.

The suspension of trading in the securities of Bioxyne Limited will be lifted immediately following release of an announcement by BXN confirming that it will not proceed with a proposed acquisition.

The Company advises that it has determined not to proceed with the proposed acquisition at this time.

The company releases a letter to its shareholders regarding its AGM.

The company's AGM will be held virtually at 11.30am AEDT on Tuesday 30 November 2021.

The securities of Bioxyne Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BXN, pending the release of an announcement regarding a potential acquisition.

The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the completion of an underwritten share placement. Security Code: BXN

The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, in accordance with listing rule 17.2, pending the release of an announcement by the Company in relation to the completion of an underwritten share placement to assist with transaction costs following the entry into a conditional non-binding proposal to acquire Vitality Devices Pty Limited. Security Code: BXN

The suspension of trading in the securities of Bioxyne Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to the results and data from its independent clinical research organisation.

company advises that its Fully Paid Ordinary shares will remain in suspension until the results of the clinical trials are fully assessed. The Company has received both the initial results and further very detailed analyses of the data. The analysis is ongoing and now requires professional validation. The Company believes that it will be in a position to release a detailed announcement after this review on Wednesday, 27 June 2012

The securities of Bioxyne Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company in relation to the results and data from its independent clinical research organisation which are continuing to be assessed.

name changed from Probiomics Limited